Systematic review on Ocrevus for treatment of multiple sclerosis

Adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) are eligible to receive therapy with ocrelizumab (Ocrevus®), an injectable humanized anti-CD20 monoclonal antibody. In pivotal trials (against interferon β-1a) and supportive single-arm studies in certain subpopulations, ocrelizumab's efficacy in lowering relapse rates and disease activity in RMS patients was established. Comparing ocrelizumab to placebo, measures of clinical and MRI progression were less in PPMS patients. Over 7.5 study years of therapy, clinical benefits were sustained. Overall, ocrelizumab was well accepted, and continued treatment hasn't shown any new safety concerns. A large body of real-world (although brief) evidence about ocrelizumab is in line with data from clinical studies.
Clinical tests. The brief, half-yearly injections of ocrelizumab are convenient. As with PPMS patients (for whom there are presently no alternative authorized DMTs), ocrelizumab remains a helpful medication for postponing the course of the disease. It is also a typically well-tolerated, very effective disease-modifying drug (DMT) for RMS.